Headlines about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive on Thursday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OraSure Technologies earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.4844655827195 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
A number of equities research analysts have recently commented on OSUR shares. Canaccord Genuity lifted their price target on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. Jefferies Group LLC raised their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, June 28th. Stephens restated an “overweight” rating and set a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Friday, September 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $18.21.
OraSure Technologies (NASDAQ OSUR) traded down 1.31% during trading on Thursday, hitting $20.37. 479,038 shares of the company were exchanged. OraSure Technologies has a 12 month low of $7.09 and a 12 month high of $23.01. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of 37.65 and a beta of 1.55. The stock’s 50-day moving average is $21.63 and its 200-day moving average is $17.96.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.02. The firm had revenue of $40.18 million during the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. OraSure Technologies’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.07 EPS. Equities research analysts anticipate that OraSure Technologies will post $0.48 earnings per share for the current year.
In related news, SVP Jack E. Jerrett sold 73,463 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $20.77, for a total transaction of $1,525,826.51. Following the transaction, the senior vice president now directly owns 81,593 shares in the company, valued at $1,694,686.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Douglas A. Michels sold 22,923 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 717,601 shares of company stock valued at $14,977,398. Company insiders own 6.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact OraSure Technologies (NASDAQ:OSUR) Share Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/10/26/orasure-technologies-osur-given-coverage-optimism-score-of-0-14.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.